What milestones enabled the evolution of TIL therapies? What does the future hold for TIL therapies? And where should you focus support for an accelerated path forward? Watch to explore these topics and more.
Here, we discuss the characterization of several representative AAV molecules using next-generation sequencing (NGS), including the sequencing process, bioinformatic analysis, and representative results.
Learn how a combination of controlled compliant workflow execution, dramatically streamlined data acquisition and an “audit by exception” approach offers the next phase of innovation within bioanalysis.
Here, we discuss the relationship between the CCS and PUPSIT, highlight the role of sterilizing grade filtration in the control strategy, and talk about how this can change throughout the product life cycle.